Lucid Diagnostics Inc
NASDAQ:LUCD
Net Margin
Lucid Diagnostics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
L
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
136.3m USD |
-1 700%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
230.3B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
182.6B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
149.8B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
143.5B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
110.7B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
51.8B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
48.3B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
43.5B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42.3B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
275.5B CNY |
31%
|
Lucid Diagnostics Inc
Glance View
Lucid Diagnostics, Inc. develops medical testing devices. The company is headquartered in New York City, New York. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. The firm is a subsidiary of PAVmed Inc.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Lucid Diagnostics Inc's most recent financial statements, the company has Net Margin of -1 699.9%.
You don't have any saved screeners yet